[en] Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, affecting a quarter of the world's adult population. NAFLD is closely related to type 2 diabetes mellitus (T2DM), obesity and metabolic syndrome. The evolution of the pathology is still uncertain, but it is known that the presence of fibrosis is the main predictor of disease progression, complications, and mortality, therefore identifying the presence of advanced fibrosis is of vital importance. Objective: to estimate the prevalence of advanced NASH in a population with DM2 and to define its phenotypic characteristics. Material and methods: the data of 577 patients with T2DM who successively attended consultations for their routine check-up were analyzed. The sample studied included 265 (45.8%) men and 312 (54.2%) women, with a mean age of 65.4 } 7.8 years, a mean BMI of 31.50 } 5.36 Kg/ m2 and a T2DM evolution time of 12.9 } 8.56 years. Subjects were clinically evaluated, 4 indirect fibrosis test were performed (APRI, NAFLD Fibrosis Score, FIB-4, Hepamet Fibrosis Score) and transient hepatic elastography through FibroscanÒ with M and XL probe. A statistical analysis of the available data was performed with SPSS R version 22. Results: a prevalence of NAFLD with advanced fibrosis (3 F3) of 10% was observed. A statistically significant association was observed between advanced fibrosis and insulin resistance (IR) values measured by HOMA2-IR as well as with the degree of BMI and AC. No statistically significant association was found with the time of evolution of T2DM or with the degree of control. Conclusions: a significant proportion of patients with T2DM may present fibrosis in advanced stages (3 F3). The degree of IR, the BMI and the PC could be predictors of risk.

[es] Introducción: la EHGNA es la causa mas comun de enfermedad hepatica cronica, afectando a una cuarta parte de la poblacion adulta mundial. La EGHNA esta estrechamente relacionada con la DM2, la obesidad y el sindrome metabolico. La evolucion de la patologia es todavia incierta, pero se conoce que la presencia de fibrosis es el principal predictor de progresion de la enfermedad, complicaciones y mortalidad, por lo que, identificar la presencia de fibrosis avanzada resulta de vital importancia. Objetivo: estimar la prevalencia de EHNA avanzada en una poblacion con DM2 y definir sus caracteristicas fenotipicas. Material y metodos: se analizaron los datos de 577 pacientes con DM2 que acudieron de forma sucesiva a consultas para su revision rutinaria. La muestra estudidada incluyo a 265 (45,8%) hombres y 312 (54,2 %) mujeres, con edad media de de 65,4 } 7,8 anos, un IMC medio de 31,50 } 5,36 Kg/m2 y un tiempo de evolucion de su DM2 de 12,9 } 8,56 anos. Los sujetos fueron evaluados clinicamente, se realizaron 4 indices indirectos de fibrosis (APRI, NAFLD Fibrosis Score, FIB-4, Hepamet Fibrosis Score) y elastrografia hepatica de transicion a traves de Fibroscanâ con sonda M y XL. Se realizo un analisis estadistico de los datos disponibles con SPSS R version 22. Resultados: se observo una prevalencia de EHGNA con fibrosis avanzada (3 F3) del 10%. Se observo una asociacion estadisticamente significativa entre la fibrosis avanzada y los valores de RI medidos por HOMA2-IR asi como con el grado de IMC y el PC. No se encontro asociacion estadisticamente significativa con el tiempo de evolucion de la DM2 ni con el grado de control de esta. Conclusiones: una proporcion significativa de los pacientes con DM2 pueden presentar fibrosis en estadios avanzados (3 F3). El grado de RI, el IMC y el PC pueden ser predictores de riesgo para evaluar los pacientes en riesgo.